Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
Stocks in this Quantisnow insightHealth Care
Historical context for BMY
Across the 24 sessions after earlier BMY headlines, the stock closed higher 13 times and lower 11 times, with a median move of 0.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BMY | SPY |
|---|---|---|---|
| May 20, 2026 | Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations | +0.4% | +1.0% |
| May 8, 2026 | Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults | -0.2% | +0.8% |
| May 6, 2026 | Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026 | -0.6% | +1.4% |
| May 4, 2026 | Bristol Myers Squibb Launches "Won't Lose" Media Campaign Ahead of FIFA World Cup 2026™ | -1.4% | -0.4% |
| Apr 30, 2026 | Bristol Myers Squibb Reports First Quarter Financial Results for 2026 | +5.2% | +1.0% |
| Apr 21, 2026 | Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion | +0.4% | -0.7% |
Quantisnow market dataNYSE
BMY
Bristol-Myers Squibb Company
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for BMY
Full BMY profile on Quantisnow Follow BMY and get a push notification the moment its next story breaks.